CureVac has signed a new licensing agreement with GSK shortly after announcing the decision to reduce its workforce by 30% and refocus its research and development priorities.
CureVac has filed a lawsuit in a German regional court against BioNTech SE: seeking ‘fair compensation for infringement… of CureVac’s intellectual property rights’ regarding tech used in the manufacture of the Pfizer/BioNTech COVID-19 vaccine. BioNTech,...
CureVac has acquired Frame Cancer Therapeutics: with the German mRNA specialist planning to draw on Frame’s expertise in antigen identification and validation as it develops mRNA cancer vaccines.
A partnership with myNEO represents the first step in CureVac’s targeted expansion of its mRNA approach for the development of cancer vaccines, says the company.
Germany has made a series of contracts with vaccine manufacturers to reserve mRNA manufacturing capacity in the country as part of its pandemic preparedness plans.
CureVac is withdrawing its first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review: instead it is re-allocating its efforts to its second-generation vaccine program with GSK. ‘The goal has not changed, but the requirements to effectively...
CureVac is streamlining its external European manufacturing network for its mRNA product pipeline; having reassessed demand for its first-generation COVID-19 vaccine candidate.
CureVac and GSK said their jointly advanced second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in a preclinical study.
German company, CureVac, says it is in ongoing dialogue with the European Medicines Agency (EMA) and is continuing regulatory submissions on its first-generation mRNA COVID-19 vaccine candidate, CVnCoV.
Preclinical data shows that CureVac’s COVID-19 vaccine protects against challenge infections with the B.1.351 ‘South Africa’ variant in a transgenic mouse model.
CureVac is expanding its late-stage clinical trials for its COVID-19 vaccine candidate; while confirming it is on schedule to apply for formal market authorization in the EU in Q2 2021.
CureVac has initiated a rolling review with the European Medicines Agency (EMA), working towards authorization for its mRNA COVID-19 vaccine in the European Union.
CureVac aims to bring together expertise from both its own company and other stakeholders to provide ‘broader and faster protection against current and future viral threats’: through collaborations with the UK Government, Bayer and GSK.
UK based pharma group, GlaxoSmithKline, and German biotech, CureVac, have struck a €150m (US$180m) deal to jointly develop next generation mRNA vaccines for COVID-19; the goal is to address multi-variants with one vaccine.
Pharmaceutical giant Bayer will support development of CureVac’s mRNA COVID-19 vaccine candidate across numerous areas: helping facilitate the global supply of several hundred million doses.
The European Commission has reached an agreement with CureVac for up to 405 million doses of its mRNA-based COVID-19 vaccine candidate: representing the biggest COVID-19 vaccine deal the Commission has inked so far.
